These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 34956081

  • 1. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.
    Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J.
    Front Endocrinol (Lausanne); 2021; 12():769187. PubMed ID: 34956081
    [Abstract] [Full Text] [Related]

  • 2. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N, Smith KP.
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [Abstract] [Full Text] [Related]

  • 3. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data.
    Schink T, Princk C, Braitmaier M, Haug U.
    BJOG; 2022 Dec; 129(13):2107-2116. PubMed ID: 35876787
    [Abstract] [Full Text] [Related]

  • 4. Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.
    Rott H.
    Hamostaseologie; 2019 Feb; 39(1):42-48. PubMed ID: 30669160
    [Abstract] [Full Text] [Related]

  • 5. Epidemiology of hormonal contraceptives-related venous thromboembolism.
    Hugon-Rodin J, Gompel A, Plu-Bureau G.
    Eur J Endocrinol; 2014 Dec; 171(6):R221-30. PubMed ID: 25012200
    [Abstract] [Full Text] [Related]

  • 6. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
    Tepper NK, Dragoman MV, Gaffield ME, Curtis KM.
    Contraception; 2017 Feb; 95(2):130-139. PubMed ID: 27771476
    [Abstract] [Full Text] [Related]

  • 7. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.
    Lancet; 1995 Dec 16; 346(8990):1589-93. PubMed ID: 7500750
    [Abstract] [Full Text] [Related]

  • 8. Thrombotic risks of oral contraceptives.
    Rott H.
    Curr Opin Obstet Gynecol; 2012 Aug 16; 24(4):235-40. PubMed ID: 22729096
    [Abstract] [Full Text] [Related]

  • 9. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
    Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME.
    Int J Gynaecol Obstet; 2018 Jun 16; 141(3):287-294. PubMed ID: 29388678
    [Abstract] [Full Text] [Related]

  • 10. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis.
    Douxfils J, Raskin L, Didembourg M, Donis N, Dogné JM, Morimont L, Beaudart C.
    Front Endocrinol (Lausanne); 2024 Jun 16; 15():1428597. PubMed ID: 39220361
    [Abstract] [Full Text] [Related]

  • 11. Combined hormonal contraception and venous thromboembolism.
    Martínez F, Avecilla A.
    Eur J Contracept Reprod Health Care; 2007 Jun 16; 12(2):97-106. PubMed ID: 17559006
    [Abstract] [Full Text] [Related]

  • 12. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR, Ory H.
    Contraception; 1997 May 16; 55(5):267-72. PubMed ID: 9220222
    [Abstract] [Full Text] [Related]

  • 13. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
    Plu-Bureau G, Sabbagh E, Hugon-Rodin J.
    Gynecol Obstet Fertil Senol; 2018 Dec 16; 46(12):823-833. PubMed ID: 30389542
    [Abstract] [Full Text] [Related]

  • 14. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
    Dinger J, Assmann A, Möhner S, Minh TD.
    J Fam Plann Reprod Health Care; 2010 Jul 16; 36(3):123-9. PubMed ID: 20659364
    [Abstract] [Full Text] [Related]

  • 15. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.
    van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K.
    J Thromb Haemost; 2016 Jul 16; 14(7):1393-403. PubMed ID: 27121914
    [Abstract] [Full Text] [Related]

  • 16. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
    Lancet; 1997 Jan 11; 349(9045):83-8. PubMed ID: 8996419
    [Abstract] [Full Text] [Related]

  • 17. Systemic hormonal contraception and risk of venous thromboembolism.
    Heikinheimo O, Toffol E, Partonen T, But A, Latvala A, Haukka J.
    Acta Obstet Gynecol Scand; 2022 Aug 11; 101(8):846-855. PubMed ID: 35633036
    [Abstract] [Full Text] [Related]

  • 18. Contraception, venous thrombosis and biological plausability.
    Rott H.
    Minerva Med; 2013 Apr 11; 104(2):161-7. PubMed ID: 23514992
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
    Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G.
    Expert Rev Clin Pharmacol; 2017 Oct 11; 10(10):1129-1144. PubMed ID: 28712325
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
    Douxfils J, Klipping C, Duijkers I, Kinet V, Mawet M, Maillard C, Jost M, Rosing J, Foidart JM.
    Contraception; 2020 Dec 11; 102(6):396-402. PubMed ID: 32956694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.